A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
Recruiting now Phase 3 NCT05897320
Run by H. Lundbeck A/S · for 6 to 17 · All sexes
What this study is about
The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.
Who can join (things the study team will check)
✅ You may be able to join if…
- Diagnosis of migraine (with or without aura) according to the International Classification of Headache Disorders, 3rd edition (ICHD-3; in the opinion of the investigator) with history of migraine headaches of at least 6 months prior to the Screening Visit.
- During the 28-day screening period, the participant (and their parent/caregiver, when applicable) must adequately complete the headache eDiary (≥23 of the 28 days) following the day of the Screening Visit.
- During the 28-day screening period, the participant must have ≤14 headache days, of which at least 4 are migraine days as documented in the eDiary.
🚫 You may not be able to join if…
- History or diagnosis of chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or unusual migraine subtypes (previously referred to as complicated migraine), such as hemiplegic migraine (sporadic and familial), migraine with brainstem aura, recurrent painful ophthalmic neuropathy, or migraine with neurological accompaniments that are not typical of migraine aura (diplopia, altered consciousness, or long duration, e.g., >60 min).
- History of moderate or severe head trauma or other neurological disorder or systemic medical disease that is, in the investigator's opinion, likely to affect the functions of the central nervous system.
- Current psychiatric condition that is uncontrolled and/or untreated for a minimum of 6 months prior to the Screening Visit. Participants with a lifetime history of psychosis and/or mania are excluded.
- Any other disorder for which the treatment takes priority over treatment of migraine or is likely to interfere with study treatment or impair treatment compliance. Other inclusion and exclusion criteria may apply.
Where this trial is running
- Ki Health Partners LLC DBA New England Institute for Clinical Research, Stamford, Connecticut, United States
- Child Neurology of NW Florida, Gulf Breeze, Florida, United States
- AGA Clinical Trials - Hialeah - 4980 W 10th Ave, Hialeah, Florida, United States
- University of South Florida - 13330 USF Laurel Dr, Tampa, Florida, United States
- Clinical Integrative Research Center of Atlanta, Atlanta, Georgia, United States
- University of Kentucky HealthCare (UKHC) Kentucky Clinic, Lexington, Kentucky, United States
- University of Maryland School of Medicine, Baltimore, Maryland, United States
- Michigan Head Pain and Neurological Institute, Ann Arbor, Michigan, United States
- North Suffolk Neurology-Commack, Commack, New York, United States
- OnSite Clinical Solutions, LLC - Randolph Rd - Charlotte, Charlotte, North Carolina, United States
- Childrens Hospital Medical Center of Akron, Akron, Ohio, United States
- Cincinnati Children's Hospital Medical Center - PIN, Cincinnati, Ohio, United States
+ 53 more sites.
Who to contact
Email contact via H. Lundbeck A/S · +45 36301311 · HQ_Medinfo@Lundbeck.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT05897320.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.